WHO enlists Globe Biotech’s coronavirus vaccine

The World Health Organization (WHO) has enlisted BANCOVID, the coronavirus vaccine developed by Bangladeshi firm Globe Biotech Limited.

The vaccine was added to the organization’s experimental landscape of Covid-19 candidate vaccines on Thursday (October 15).

According to WHO’s draft list of possible vaccines for coronavirus, 198 different vaccines are being developed in different countries. Of the vaccines, 156are in early stage and 42 are in the experimental stage.

It was learned that Globe Biotech is the only company in the world listed with three vaccine candidates - DNA plasmid vaccine, Adenovirus Type 5 Vector and D614G variant LNP-encapsulated mRNA, according to a press release.

A memorandum of understanding (MoU) was signed between International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR, B) and the Globe Biotech for human trial of the vaccine. At the time, Globe reported that ICDDR, B, would review the results of a trial on animals. Both sides will look at and review the results of the tests that have been done, especially on animals. The protocol of the clinical trial will be reviewed later. If the results of this review are satisfactory, permission will be sought from the Bangladesh Medical and Research Council (BMRC) and the Department of Drug Administration for the human body trial. If permission is obtained, the work of clinical trial on human body will start.